Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 10/20 | 0.62 |
| ▸ | AR | P10275 | 5/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6610436 | 0.84 | PARP1 (0.62) | PARP1ARTSHRLMNACYP3A4 | |
| SCHEMBL26907192 | 0.83 | TSHR (0.66) | PARP1ARTSHRLMNACYP3A4 | |
| SCHEMBL4573019 | 0.81 | PARP1 (0.70) | PARP1ARTSHRLMNACYP3A4 | |
| SCHEMBL29655200 | 0.81 | PARP1 (0.70) | PARP1ARTSHRLMNACYP3A4 | |
| SCHEMBL26907276 | 0.81 | PARP1 (0.58) | PARP1ARTSHRLMNACYP3A4 | |
| SCHEMBL76707 | 0.81 | PARP1 (0.62) | PARP1ARTSHRLMNACYP3A4 | |
| SCHEMBL8270690 | 0.81 | PARP1 (0.58) | PARP1ARTSHRLMNACYP3A4 | |
| SCHEMBL905630 | 0.80 | AR (0.79) | PARP1ARTSHRLMNACYP3A4 | |
| SCHEMBL8154178 | 0.79 | AR (0.77) | PARP1ARTSHRLMNACYP3A4 | |
| SCHEMBL19748563 | 0.78 | ENPP1 (0.64) | PARP1ARTSHRLMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280910-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080280910-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080280910-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| WO-2008114023-A2 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280910-A1 | PHTHALAZINONE DERIVATIVES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SDHA, NCOA4 | PARP1 3512/4885AR 392/4885TSHR 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.